Anti-wrinkle composition containing palmitoyl hexapeptide-12 as well as preparation method and application of anti-wrinkle composition

Abstract

The invention discloses an anti-wrinkle composition containing palmitoyl hexapeptide-12 as well as a preparation method and application of the anti-wrinkle composition, and relates to the technical field of cosmetics. The composition comprises palmitoyl hexapeptide-12, a butterflybush flower extract, a sparassis crispa extract and a rosa roxburghii tratt fruit extract. The palmitoyl hexapeptide-12, the buddleja officinalis extract, the sparassis crispa extract and the rosa roxburghii tratt fruit extract can synergistically promote fibroblasts to synthesize type I collagen, reduce the area of wrinkles, reduce the maximum length value of the wrinkles and effectively delay skin aging, and the skin care product is non-irritant, has good safety and is suitable for sensitive skin.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of cosmetics, in particular to an anti-wrinkle composition containing palmitoyl hexapeptide-12 and a preparation method and application thereof. BACKGROUND

[0002] With the growth of age, the body metabolism slows down, and the skin will gradually produce wrinkles and the like. In order to improve the aging condition of the skin, cosmetics with anti-wrinkle function are favored by the public. Type I collagen is the most abundant protein in the extracellular matrix of dermal cells, providing support for cell adhesion and anchoring of macromolecules. By promoting the synthesis of type I collagen, the formation of wrinkles can be effectively reduced. However, the current anti-wrinkle products have limited effect due to the use of single component, or the skin is irritated due to the excessive use of certain functional components, which is not conducive to the use of sensitive skin. Therefore, it is necessary to provide a product with anti-wrinkle function and no irritation. SUMMARY

[0003] The present application aims to at least solve one of the technical problems existing in the prior art. To this end, the present application proposes a composition.

[0004] The present application also provides a preparation method of the above-mentioned composition.

[0005] The present application also provides the use of the above-mentioned composition in the preparation of skin care preparations.

[0006] The present application also provides a cosmetic comprising the above-mentioned composition.

[0007] According to the composition of the first aspect of the present application, it comprises: palmitoyl hexapeptide-12, Buddleja officinalis extract, Sparassis crispa extract, and Rosa roxburghii fruit extract.

[0008] According to the composition of the present application, at least the following beneficial effects are achieved: The composition of the present application can synergistically promote the synthesis of type I collagen by fibroblasts, reduce the area of wrinkles, reduce the maximum length value of wrinkles, effectively delay skin aging, and has no irritation, good safety, and is suitable for sensitive skin.

[0009] According to some embodiments of the present application, the composition comprises, by mass fraction: 5-8 parts of palmitoyl hexapeptide-12, 0.05-0.7 parts of Buddleja officinalis extract, 0.5-3 parts of Sparassis crispa extract, and 1-2.5 parts of Rosa roxburghii fruit extract.

[0010] According to some embodiments of the present application, the composition comprises, by mass fraction: 5.5-7 parts of palmitoyl hexapeptide-12, 0.1-0.6 parts of Buddleja officinalis extract, 1-2.5 parts of Sparassis crispa extract, and 1.4-1.9 parts of Rosa roxburghii fruit extract.

[0011] According to some embodiments of the present application, the composition comprises, by mass fraction: 5.8-6.2 parts of palmitoyl hexapeptide-12, 0.45-0.55 parts of Buddleja officinalis extract, 1.8-2.2 parts of Sambucus williamsii extract, 1.45-1.6 parts of Rosa roxburghii fruit extract.

[0012] The method for preparing the composition according to the first aspect of the second aspect of the embodiments of the present application comprises the following step: mixing the components.

[0013] The use of the composition according to the first aspect of the third aspect of the embodiments of the present application in the preparation of a skin care preparation.

[0014] According to some embodiments of the present application, the skin care preparation has at least one of the following uses: A1) promoting collagen type I synthesis; A2) anti-photoaging; A3) anti-wrinkle.

[0015] A cosmetic according to the fourth aspect of the embodiments of the present application comprises the composition according to the first aspect of the embodiments of the present application and a cosmetically acceptable adjuvant. Since the cosmetic adopts all the technical solutions of the composition according to the above embodiments, it at least has all the beneficial effects brought by the technical solutions of the above embodiments.

[0016] According to some embodiments of the present application, the cosmetic is a cosmetic water, serum, emulsion, cream or mask.

[0017] According to some embodiments of the present application, the mass fraction of the composition is 0.1%-20% based on the total mass of the cosmetic. For example, it can be 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19% or 20%.

[0018] According to some embodiments of the present application, the adjuvant comprises at least one of the following: emollients, emulsifiers, thickeners, humectants, pH adjusters, skin protectants and preservatives.

[0019] Other features and advantages of the present application will be set forth in the specification, and in part will become apparent to those skilled in the art upon reference to it, or will be learned by practice of the application. DETAILED DESCRIPTION

[0020] The concept and the technical effects of the present application will be described clearly and completely in combination with the embodiments, so as to fully understand the purpose, features and effects of the present application. Obviously, the described embodiments are only a part of the embodiments of the present application, but not all the embodiments. Based on the embodiments of the present application, other embodiments obtained by those skilled in the art without creative labor are within the protection scope of the present application.

[0021] The specific conditions not mentioned in the embodiments are carried out according to the conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments used are not mentioned by the manufacturer, which are conventional products that can be obtained by market purchase.

[0022] When a numerical range is disclosed herein, the above range is considered to be continuous and includes the minimum value and the maximum value of the range, and each value between the minimum value and the maximum value. Further, when the range refers to an integer, each integer between the minimum value and the maximum value of the range is included. In addition, when multiple ranges are provided to describe a feature or a characteristic, the ranges can be combined. In other words, unless otherwise indicated, all ranges disclosed herein should be understood to include any and all sub-ranges subsumed therein.

[0023] "Quality parts" refer to the basic unit of measurement indicating the mass ratio relationship of multiple components, 1 part can represent any unit mass, such as 1 g, 2.689 g, etc. If we say that the mass of component A is a parts, and the mass of component B is b parts, it means that the mass ratio of component A to component B is a:b. Or, the mass of component A is aK, and the mass of component B is bK (K is an arbitrary number, indicating a multiple factor). It should not be misunderstood that unlike the mass fraction, the sum of the mass of all components is not limited to 100 parts.

[0024] In the following examples, palmitoyl hexapeptide-12, INCI name: palmitoyl hexapeptide-12; Buddleja officinalis extract, INCI name: Buddleja officinalis extract; Sparassis crispa extract, INCI name: Sparassis crispa extract; Rosa roxburghii fruit extract, INCI name: Rosa roxburghii fruit extract.

[0025] Example This example provides three compositions of Examples 1-3, the composition is shown in Table 1 in weight parts.

[0026] Table 1

[0027] Comparative Example 1 This example provides a composition, which is substantially the same as the composition of Example 1, except that equal mass of water is substituted for palmitoyl hexapeptide-12.

[0028] Comparative Example 2 This example provides a composition, which is substantially the same as the composition of Example 1, except that equal mass of water is substituted for Buddleja officinalis extract.

[0029] Comparative Example 3 This example provides a composition, which is substantially the same as the composition of Example 1, except that equal mass of water is substituted for Galbulin extract.

[0030] Comparative Example 4 This example provides a composition, which is substantially the same as the composition of Example 1, except that equal mass of water is substituted for Rosa roxburghii fruit extract.

[0031] Application Example 1 This example provides a toner, the composition of which is shown in Table 2.

[0032] Table 2

[0033] This application example also provides a preparation method of the toner, which comprises the following steps: Glycerin, butanediol, oxybenzene propyl ester are stirred and dissolved to be transparent at 60-65℃, and then cooled to below 40℃ to obtain phase A; PEG-40 hydrogenated castor oil, PPG-26-butanediol polyether-26, and essence are stirred and dispersed uniformly to obtain phase B; disodium EDTA, hyaluronic acid, glycerol, panthenol, allantoin, p-hydroxyacetophenone, palmitoyl hexapeptide-12, Buddleja officinalis extract, Galbulin extract, Rosa roxburghii fruit extract, and water are stirred and dispersed uniformly, and then phase A and phase B are continuously added and stirred to be uniformly dispersed; after inspection, the toner is filtered through a 300-mesh sieve to obtain the toner.

[0034] Application Example 2 This application example provides a toner, which is substantially the same as the toner of Application Example 1, except that the composition of Example 1 is replaced by equal mass of the composition of Example 2.

[0035] Application Example 3 This application example provides a toner, which is substantially the same as the toner of Application Example 1, except that the composition of Example 1 is replaced by equal mass of the composition of Example 3.

[0036] Application Comparative Example 1 The present application example provides a cosmetic water, which is basically the same as the application example 1, with the difference that the composition of example 1 is replaced by the composition of comparative example 1 in equal mass.

[0037] Application Comparative Example 2 The present application example provides a cosmetic water, which is basically the same as the application example 1, with the difference that the composition of example 1 is replaced by the composition of comparative example 2 in equal mass.

[0038] Application Comparative Example 3 The present application example provides a cosmetic water, which is basically the same as the application example 1, with the difference that the composition of example 1 is replaced by the composition of comparative example 3 in equal mass.

[0039] Application Comparative Example 4 The present application example provides a cosmetic water, which is basically the same as the application example 1, with the difference that the composition of example 1 is replaced by the composition of comparative example 4 in equal mass.

[0040] Application Comparative Example 5 The present application example provides a cosmetic water, which is basically the same as the application example 1, with the difference that the composition of example 1 is replaced by water in equal mass.

[0041] Test Example 1 Human dermal fibroblasts (HDF-α) were inoculated in 6-well plates at 1×10 5 cells / well, and incubated in an incubator (37℃, 50% CO2) overnight. The culture solution was discarded, and DMEM medium containing 1(w / v)% of the composition of examples 1-3 and comparative examples 1-4 was added to the experimental groups, respectively, and the culture was continued for 24 h; the blank control group and the model control group were treated with the same amount of DMEM medium. Then, UVA irradiation (irradiation intensity of 30 J / cm 2 ) was performed on each experimental group and the model control group, and the culture was continued for 24 h. The cell supernatant was collected, and the synthesis amount of collagen type I in each group was detected by ELISA technology, and the synthesis growth rate of collagen type I in each group was calculated (synthesis growth rate (%) = (synthesis amount of the experimental group or the blank control group / synthesis amount of the model control group-1) × 100%). Three replicate wells were set in each group, and the experiment was repeated three times.

[0042] The results are shown in Table 3. The results are expressed as mean values.

[0043] Table 3

[0044] The compositions of Examples 1-3 can significantly promote the synthesis of collagen type I by human dermal fibroblasts.

[0045] Test Example 2 Thirty volunteers were selected, and the age and gender of the volunteers were randomly determined, in accordance with the standards of the “Cosmetic Safety Technical Specifications” (2015 edition). The safety of the cosmetic water (0.02 mL) of Examples 1-3 and Comparative Examples 1-5 was tested according to the skin occlusive patch test of the “Human Skin Patch Test” of the “Cosmetic Safety Technical Specifications” (2015 edition).

[0046] The results are shown in Table 4.

[0047] Table 4

[0048] After using the cosmetic water of Examples 1-3 and Comparative Examples 1-5, all volunteers had no adverse reactions. This indicates that the cosmetic water of Examples 1-3 and Comparative Examples 1-5 has good safety.

[0049] Test Example 3 240 volunteers (aged 35-50 years, 120 males and 120 females) who met the inclusion criteria of the test volunteers were selected and randomly divided into 8 groups, and the cosmetic water of Examples 1-3 and Comparative Examples 1-5 was tested. After washing the face, 0.5 g of the test product was used, once in the morning and once in the evening, for 28 consecutive days, and other products with similar functions were avoided. After use, sit still for 30 min in a condition of 50±5% humidity and temperature 26±1℃, take a photo with VISIA, measure the total wrinkle area value of the volunteers before and after use, and calculate the total wrinkle area change rate and the maximum wrinkle length value change rate.

[0050] The total wrinkle area change rate (%) = (total wrinkle area after 28 days of use / total wrinkle area on day 0-1) x 100%; The maximum wrinkle length value change rate (%) = (maximum wrinkle length value after 28 days of use / maximum wrinkle length value on day 0-1) x 100%.

[0051] The results are shown in Table 5. The results are expressed as the average value.

[0052] Table 5

[0053] After the volunteers use the test substance for 28 days, the total wrinkle area and the maximum length value of the wrinkle are significantly reduced, and the anti-wrinkle effect is good, and the lack of any one of palmitoyl hexapeptide-12, buddleja officinalis extract, cistus extract and roxburgh rose fruit extract will significantly reduce the effect. This shows that palmitoyl hexapeptide-12, buddleja officinalis extract, cistus extract and roxburgh rose fruit extract have significant synergistic effect in anti-wrinkle.

[0054] The above describes the embodiments of the present application in detail in combination with the examples, but the present application is not limited to the above examples, and various changes can be made within the knowledge range possessed by those skilled in the art without departing from the purpose of the present application.

Claims

1. A composition, characterized in that, include: Palmitoyl hexapeptide-12, Buddleja officinalis extract, Hydrangea macrophylla extract, Prickly pear fruit extract.

2. The composition according to claim 1, characterized in that, The composition comprises, by weight parts: 5-8 parts palmitoyl hexapeptide-12, 0.05-0.7 parts Buddleja officinalis extract, 0.5-3 parts Hydrangea macrophylla extract, and 1-2.5 parts Prickly pear fruit extract.

3. The composition according to claim 1, characterized in that, The composition comprises, by weight parts: 5.5-7 parts palmitoyl hexapeptide-12, 0.1-0.6 parts Buddleja officinalis extract, 1-2.5 parts Hydrangea macrophylla extract, and 1.4-1.9 parts Prickly pear fruit extract.

4. The composition according to claim 1, characterized in that, The composition comprises, by weight parts: 5.8-6.2 parts palmitoyl hexapeptide-12, 0.45-0.55 parts Buddleja officinalis extract, 1.8-2.2 parts Hydrangea macrophylla extract, and 1.45-1.6 parts Prickly pear fruit extract.

5. A method for preparing the composition according to any one of claims 1 to 4, characterized in that, Includes the following steps: Mix the components together.

6. Use of the composition according to any one of claims 1 to 4 in the preparation of skin care formulations.

7. A cosmetic product, characterized in that, The cosmetic product comprises the composition according to any one of claims 1 to 4 and cosmetically acceptable excipients.

8. The cosmetic product according to claim 7, characterized in that, The cosmetics mentioned are toners, serums, lotions, creams, or masks.

9. The cosmetic product according to claim 7, characterized in that, The composition comprises 0.1% to 20% by mass based on the total mass of the cosmetic.

10. The cosmetic product according to claim 7, characterized in that, The excipients include at least one of emollients, emulsifiers, thickeners, humectants, pH adjusters, skin protectants, and preservatives.

Images